Replies to post #165675 on Biotech Values

[poorgradstudent]

ONXX / AMGN:

I'm still a bit surprised that there isn't a CVR along with this deal. I understand ONXX's reticence to ask for one, but AMGN now has a lot riding on carfilzomib and it's 3 in-progress trials. I think it's a good drug, and the royalties from the other programs should ease some nerves, but still...